Introduction
============

Patients with locally advanced breast cancer, which is defined as stage III disease, had a higher risk for locoregional recurrence (LRR). Approximately 30% of patients with high-risk breast cancer develop LRR after mastectomy, but the administration of postmastectomy radiotherapy (PMRT) may reduce LRR and improve survival outcomes.[@b1-cmar-10-2047]--[@b3-cmar-10-2047] In these high-risk patients, the interval between PMRT administration and mastectomy may affect LRR and survival outcomes. However, the optimal time between surgery and PMRT remains unclear.

There are conflicting results regarding the optimal interval between surgery and radiotherapy. However, it has been reported that an interval \>6--12 weeks in patients not receiving chemotherapy, and an interval \>6--7 months in patients receiving adjuvant chemotherapy after surgery, may lead to a higher risk of recurrence.[@b4-cmar-10-2047]--[@b9-cmar-10-2047] Several retrospective studies have yielded variable findings in women receiving breast-conserving surgery.[@b5-cmar-10-2047],[@b10-cmar-10-2047]--[@b14-cmar-10-2047] Adjuvant chemotherapy and radiotherapy is the standard treatment for high-risk breast cancer after mastectomy.[@b15-cmar-10-2047] In this study, we retrospectively assessed the long-term survival effect of the surgery--PMRT interval in women with locally advanced breast cancer treated with mastectomy and adjuvant chemotherapy.

Materials and methods
=====================

Patients
--------

We retrospectively analyzed the medical data of patients with breast cancer who underwent mastectomy between 1999 and 2009 at the Sun Yat-Sen University Cancer Center, Guangzhou, China. Patients were eligible for inclusion in this study if: in accordance with the current tumor (T) node (N) metastasis (M) staging system, they had stage III breast cancer;they underwent mastectomy, and at least 4 cycles adjuvant chemotherapy followed by PMRT;PMRT was administrated to the chest wall and supraclavicular lymph nodes to a prescription dose of 50 Gy in 25 fractions; andthey had complete clinicopathologic and follow-up data.All patients gave their written informed consent to use of their medical records, and the clinical ethics committee of the Sun Yat-sen University Cancer Center approved this study.

Clinicopathologic factors
-------------------------

The following clinicopathologic factors were included: age; menopausal status; tumor stage; hormone receptor (HoR) status; and human epidermal growth factor receptor-2 (HER2) status. The expressions of estrogen receptor (ER), progesterone receptor (PR), and HER2 were assessed in accordance with our previous study.[@b16-cmar-10-2047] ER and PR positivity were defined as immunohistochemistry findings of \>1% positive cells. HER2 positivity was defined as an immunohistochemistry score of 3+ or 2+ with confirmation by fluorescence in situ hybridization. The breast cancer subtypes (BCS) were classified as four subtypes according to HoR and HER2 status: HoR+/HER2−, HoR+/HER2+, HoR−/HER2+, and HoR−/HER2− subtypes. Based on the interval between mastectomy and radiotherapy, the patients were classified into three groups: Group 1 (≤4 vs \>4 months), Group 2 (≤5 vs \>5 months), and Group 3 (≤6 vs \>6 months). The primary endpoints of this study were locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). LRR was defined as pathologically confirmed recurrence including ipsilateral chest wall, axillary lymph nodes, supraclavicular and subclavian lymph nodes, or internal mammary lymph nodes. Distant metastasis was defined as tumor recurrence at a site distal to the primary cancer. DFS referred to absence of LRR or distant metastasis. OS was defined as the time from initial diagnosis to the date of death or last follow-up.

Statistical analysis
--------------------

The *χ*^2^-test or Fisher's exact test was performed to compare differences between the three interval groups. The survival curves were estimated using the Kaplan--Meier method and compared using the log-rank test. Univariate and multivariate Cox regression analyses were performed to investigate the risk factors for survival outcomes. In the univariate analysis, the survival differences were investigated according to age, menopausal status, tumor stage, BCS, and timing of PMRT administration. Multivariate Cox regression analyses were then performed to identify the independent predictors from those statistically significant in the univariate analysis. Statistical analyses were performed using SPSS (version 21.0; IBM Corporation, Armonk, NY, USA). A *P* value \<0.05 was considered statistically significant.

Results
=======

A total of 340 patients were included in this study. The characteristics of the patients are presented in [Table 1](#t1-cmar-10-2047){ref-type="table"}. Their median age was 45 years (range, 24--74 years), and 65.3% were premenopausal. There were 168 (49.4%), 14 (4.1%), and 158 (46.5%) patients with IIIA, IIIB, and IIIC stage disease, respectively. There were 52.1%, 21.2%, 14.1%, and 12.6% of patients with HoR+/HER2−, HoR+/HER2+, HoR−/HER2+, and HoR−/HER2− subtypes, respectively.

All patients underwent mastectomy, axillary lymph node dissection, adjuvant chemotherapy, and PMRT. Most of the patients (98.2%) received anthracycline-and-taxane-based chemotherapy, and the median of chemotherapy courses was 6 (range, 4--12). Patients with HoR-positive disease received endocrine therapy, and only two patients with HER2-positive disease were treated with trastuzumab-containing regimens. All patients received PMRT to the chest wall and supraclavicular lymph nodes. The internal mammary lymph nodes were not routinely irradiated.

The median surgery--PMRT interval was 5 months (range, 3--15 months). Patient characteristics by surgery--PMRT interval are listed in [Table 1](#t1-cmar-10-2047){ref-type="table"}. In Group 1 (n = 78 in ≤4 months, n = 262 in \>4 months), there were no significant differences in patient characteristics between the two cohorts. In Group 2 (n = 204 in ≤5 months, n = 136 in \>5 months), patients with a surgery--PMRT interval \>5 months were more likely to be aged ≥50 years and receive \>6 cycles of chemotherapy. In addition, in Group 3 (n = 285 in ≤6 months, n = 55 in \>6 months), patients with a surgery--PMRT interval \>6 months were more likely to receive \>6 cycles of chemotherapy.

The median follow-up time was 79.8 months (range, 5--166 months). A total of 36 patients developed LRR, and the 10-year LRFS was 86.3%. The details on event distribution of LRR and distant metastasis are listed in [Table 2](#t2-cmar-10-2047){ref-type="table"}. The 10-year DMFS, DFS, and OS were 60.6%, 51.5%, and 61.1%, respectively.

[Table 3](#t3-cmar-10-2047){ref-type="table"} shows the univariate analyses of survival outcomes. The surgery--PMRT interval including Group 1, Group 2, and Group 3 was not significantly associated with LRFS, DMFS, DFS, or OS. In addition, in the subgroup analysis of the effect of surgery--PMRT interval on survival outcomes according to various clinicopathologic factors, the surgery--PMRT interval was also not associated with survival outcomes in different age groups, tumor stage, and BCS. The survival curves in Group 1, Group 2, and Group 3 are shown in [Figures 1](#f1-cmar-10-2047){ref-type="fig"}[](#f2-cmar-10-2047){ref-type="fig"}--[3](#f3-cmar-10-2047){ref-type="fig"}, respectively. The BCS was the independent significant predictor for LRFS, menopausal status, tumor stage, and BCS were the independent significant predictors for DMFS and DFS, while age, tumor stage, and BCS were the independent significant predictors for OS.

Discussion
==========

In this study, we assessed the long-term survival effect of the interval between surgery and PMRT in women with locally advanced breast cancer. Our results showed that the delay in the start of PMRT in locally advanced breast cancer is not related to an increased risk of LRR, distant recurrence, or death.

Reportedly, \~50% of patients experience delayed postoperative radiotherapy.[@b17-cmar-10-2047] For ethical reasons, it is impossible to conduct a randomized controlled trial to assess the effect of the surgery--radiotherapy interval on survival outcomes in patients with breast cancer. Hence, the optimal surgery--radiotherapy interval remains unclear. Theoretically, the risk of LRR or distant recurrence is related to the residual tumor burden in the surgical bed. Therefore, a long interval before PMRT after breast surgery may increase the likelihood of residual tumor growth and the development of radioresistance, consequently leading to a poorer outcome.[@b18-cmar-10-2047],[@b19-cmar-10-2047]

Controversy continues to surround the surgery--radiotherapy interval in patients with breast cancer who receive breast-conserving surgery. In the International Breast Cancer Study Group trials, the timing of radiotherapy after breast-conserving surgery was not significantly associated with the LRFS, DFS, and OS of patients who received initial chemotherapy or endocrine therapy.[@b10-cmar-10-2047],[@b11-cmar-10-2047] Two population-based cohort studies also found that starting radiotherapy shortly after breast-conserving surgery did not improve the long-term survival outcomes of patients with or without chemotherapy.[@b13-cmar-10-2047],[@b14-cmar-10-2047] However, a meta-analysis indicated that delayed radiotherapy after breast-conserving surgery was associated with a significantly higher risk of LRR.[@b12-cmar-10-2047] In addition, a population-based study of the Surveillance Epidemiology and End Results Program that included 18,050 women with stage 0--II disease after breast-conserving surgery and radiotherapy (but not chemotherapy) showed that an interval \>6 weeks was associated with an increased likelihood of LRR.[@b5-cmar-10-2047] These results suggest that radiotherapy should be initiated as soon as possible after breast-conserving surgery in patients not receiving chemotherapy.

Approximately 30% of locally advanced breast cancer may develop LRR after mastectomy, but the administration of PMRT may reduce LRR and decrease the incidence of systemic relapse.[@b1-cmar-10-2047]--[@b3-cmar-10-2047] The optimal interval between mastectomy and PMRT in patients with locally advanced disease remains unclear. However, several retrospective studies have shown that the interval between mastectomy and PMRT in patients with locally advanced breast cancer is not associated with survival outcomes. Kim et al[@b20-cmar-10-2047] after examining 275 patients with stage I--IIIB disease treated with chemotherapy and PMRT found that delaying the start of PMRT (≤2 vs \>2 months and ≤6 vs \>6 months) did not affect LRR or survival outcomes. Metz et al[@b21-cmar-10-2047] assessed 221 patients with locally advanced breast cancer who received mastectomy and showed that delayed PMRT did not adversely affect LRR at 8 years. The rates of LRR at 8 years were 13%, 4%, and 12% in patients with surgery--PMRT intervals of ≤2, 2.1--6, and \>6 months, respectively (*P* = 0.51).[@b21-cmar-10-2047] Desai et al[@b22-cmar-10-2047] examined 248 patients and demonstrated no significant effect of the surgery--PMRT interval on LRR in patients who underwent neoadjuvant chemotherapy and mastectomy.

The participants of this study were classified based on the interval between surgery and the initiation of PMRT. Our findings indicated that the survival benefit of PMRT is maintained up to 6 months. Our findings were similar to those of the aforementioned studies.[@b20-cmar-10-2047]--[@b22-cmar-10-2047] That is, the survival outcomes and patterns of treatment failure did not differ according to the interval between mastectomy and PMRT. The German Society for Radiooncology recommends that PMRT should be started 4--6 weeks after surgery or completion of the primary or adjuvant chemotherapy.[@b23-cmar-10-2047] Although the optimal interval between mastectomy and PMRT cannot be determined from the available evidence, patient anxiety is related to the waiting time for PMRT; thus, we propose that patients start PMRT as soon as possible after mastectomy.

Delayed administration of PMRT can result from various social and patient factors, including a lack of adequate equipment and personnel, treatment at cancer centers, a desire for breast reconstruction, and the problem of wound healing, which lead to long waiting lists.[@b24-cmar-10-2047] Although timely access to PMRT remains a priority for all centers, the clinical efficacy of PMRT is maintained even when the start of PMRT is delayed. PMRT should still be administered to patients who have experienced a delay but have not developed LRR.[@b22-cmar-10-2047]

The primary limitation of our study is its retrospective nature from a single institution; however, the effect of the surgery--radiotherapy interval on survival is a subject ethically inappropriate for randomized studies. Therefore, retrospective studies are a reasonable choice to confirm the impact of the surgery--radiotherapy interval on breast cancer recurrence. In addition, this study was limited by its small sample size and limited follow-up time. Moreover, most of the patients with HER2-positive disease did not receive trastuzumab-based treatment, which was the standard of care in the modern series; therefore, the results of this study are less applicable to the general population of breast cancer patients.

Conclusion
==========

In conclusion, our results suggest that the delay in the start of PMRT in locally advanced breast cancer does not increase the likelihood of LRR, distant metastasis, and death.
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###### 

Baseline characteristics according to interval category (n = 340)

  Characteristic                   n     Group 1     Group 2      Group 3                                                                
  -------------------------------- ----- ----------- ------------ --------- ------------ ------------ --------- ------------ ----------- -------
  Age (years)                                                                                                                            
   \<35                            43    11 (14.1)   32 (12.2)    0.372     33 (16.2)    10 (7.4)     0.032     37 (13.0)    6 (10.9)    0.716
   35--49                          178   45 (57.7)   133 (50.8)             107 (52.5)   71 (52.2)              151 (53.0)   27 (49.1)   
   ≥50                             119   22 (28.2)   97 (37.0)              64 (31.4)    55 (40.4)              97 (34.0)    22 (40.0)   
  Menopausal status                                                                                                                      
   Premenopausal                   222   54 (69.2)   168 (64.1)   0.420     141 (69.1)   81 (59.6)    0.081     189 (66.3)   33 (60.0)   0.439
   Postmenopausal                  118   24 (30.8)   94 (35.9)              63 (30.9)    55 (40.4)              96 (33.7)    22 (40.0)   
  Tumor stage                                                                                                                            
   IIIA                            168   36 (46.2)   132 (50.4)   0.768     103 (50.5)   65 (47.8)    0.541     143 (50.2)   25 (45.5)   0.868
   IIIB                            14    3 (3.8)     11 (4.2)               10 (4.9)     4 (2.9)                12 (4.2)     2 (3.6)     
   IIIC                            158   39 (50.0)   119 (45.4)             91 (44.6)    67 (49.3)              130 (45.6)   28 (50.9)   
  Breast cancer subtype                                                                                                                  
   HoR+/HER2−                      177   41 (52.6)   136 (51.9)   0.392     104 (51.0)   73 (53.7)    0.397     148 (51.9)   29 (52.7)   0.930
   HoR+/HER2+                      72    17 (21.8)   55 (21.0)              48 (23.5)    24 (17.6)              61 (21.4)    11 (20.0)   
   HoR−/HER2+                      48    14 (17.9)   34 (13.0)              30 (14.7)    18 (13.2)              39 (13.7)    9 (16.4)    
   HoR−/HER2−                      43    6 (7.7)     37 (14.1)              22 (10.8)    21 (15.4)              37 (13.0)    6 (10.9)    
  Chemotherapy regime                                                                                                                    
   CMF                             6     3 (3.8)     3 (1.1)      0.136     4 (2.0)      2 (1.5)      1.000     5            1 (1.8)     1.000
   Anthracycline/taxane regimens   334   75 (96.2)   259 (98.9)             200 (98.0)   134 (98.5)             280          54 (98.2)   
  Chemotherapy courses                                                                                                                   
   4--6                            277   70 (89.7)   209 (79.8)   0.063     183 (89.7)   96 (70.6)    \<0.001   242 (84.9)   37 (67.3)   0.003
   \>6                             61    8 (10.3)    53 (20.2)              21 (10.3)    40 (29.4)              43 (15.1)    18 (32.7)   

**Abbreviations:** CMF, cyclophosphamide, epirubicin/adriamycin, fluorouracil; HER2, human epidermal growth factor receptor-2; HoR, hormone receptor.

###### 

The details on event distribution between groups

  Recurrence site                      Group 1     Group 2     Group 3                              
  ------------------------------------ ----------- ----------- ----------- ----------- ------------ -----------
  LRR (single site)                                                                                 
   Chest wall                          1 (1.3)     12 (4.6)    8 (3.9)     5 (3.7)     9 (3.2)      4 (7.3)
   Supra-/infraclavicular lymph node   3 (3.8)     6 (2.3)     5 (2.5)     4 (2.9)     9 (3.2)      0 (0)
   Internal mammary lymph node         0 (0)       0 (0)       0 (0)       0 (0)       0 (0)        0 (0)
   Axillary lymph node                 2 (2.5)     2 (0.7)     3 (1.5)     1 (0.7)     3 (1.1)      1 (1.8)
   LRR (≥2 LRR sites)                  3 (3.8)     7 (2.7)     8 (3.9)     2 (1.5)     10 (3.5)     0 (0)
   Distant metastasis                  27 (34.6)   89 (34.0)   75 (36.8)   41 (30.1)   100 (35.1)   16 (29.1)

**Abbreviation:** LRR, locoregional recurrence.

###### 

Univariate Cox regression analysis of prognostic factors

  Characteristic          LRFS                   DMFS    DFS                    OS                                                                
  ----------------------- ---------------------- ------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  Age (years)                                                                                                                                     
   \<35                   1                              1                                1                                1                      
   35--49                 0.553 (0.197--1.551)   0.260   0.771 (0.427--1.392)   0.388     0.628 (0.384--1.027)   0.064     0.467 (0.268--0.814)   0.007
   ≥50                    1.277 (0.474--3.441)   0.629   1.303 (0.720--2.358)   0.381     1.004 (0.610--1.654)   0.987     0.890 (0.515--1.538)   0.677
  Menopausal status                                                                                                                               
   Premenopausal          1                              1                                1                                1                      
   Postmenopausal         1.798 (0.934--3.461)   0.079   1.519 (1.050--2.196)   0.026     1.429 (1.026--1.989)   0.035     1.416 (1.017--1.972)   0.040
  Tumor stage                                                                                                                                     
   IIIA                   1                              1                                1                                1                      
   IIIB                   0.968 (0.127--7.379)   0.975   1.682 (0.665--4.258)   0.272     1.382 (0.521--3.465)   0.490     1.635 (0.651--4.110)   0.296
   IIIC                   1.878 (0.954--3.697)   0.068   2.171 (1.478--3.189)   \<0.001   2.308 (1.639--3.252)   \<0.001   2.365 (1.675--3.340)   \<0.001
  Breast cancer subtype                                                                                                                           
   HR+/HER2−              1                              1                                1                                1                      
   HR+/HER2+              1.522 (0.599--3.867)   0.378   1.265 (0.763--2.096)   0.362     1.086 (0.691--1.708)   0.720     0.999 (0.635--1.570)   0.995
   HR−/HER2+              2.835 (1.157--6.941)   0.023   2.349 (1.438--3.836)   0.001     2.004 (1.290--3.114)   0.002     1.634 (1.048--2.547)   0.030
   HR−/HER2−              3.773 (1.586--8.977)   0.003   2.330 (1.405--3.864)   0.001     1.833 (1.150--2.923)   0.011     1.882 (1.180--3.001)   0.008
  Treatment interval                                                                                                                              
   ≤4 months              1                              1                      1         1                                1                      
   \>4 months             0.885 (0.416--1.884)   0.752   1.001 (0.650--1.541)   0.998     0.954 (0.654--1.393)   0.808     0.966 (0.630--1.575)   0.988
  Treatment interval                                                                                                                              
   ≤5 months              1                              1                                1                                1                      
   \>5 months             0.725 (0.362--1.452)   0.365   0.769 (0.525--1.126)   0.177     0.905 (0.648--1.265)   0.559     0.918 (0.618--1.365)   0.674
  Treatment interval                                                                                                                              
   ≤6 months              1                              1                                1                                1                      
   \>6 months             0.804 (0.313--2.069)   0.651   0.765 (0.451--1.296)   0.319     0.789 (0.492--1.266)   0.327     0.688 (0.385--1.231)   0.208

**Abbreviations:** DFS, disease-free survival; DMFS, distant metastasis-free survival; HER2, human epidermal growth factor receptor-2; HoR, hormone receptor; HR, hazard ratio; LRFS, locoregional recurrence-free survival; OS, overall survival.
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